Smith & Nephew’s (SN) “Sector perform” Rating Reaffirmed at Royal Bank Of Canada

Smith & Nephew (LON:SN – Get Free Report)‘s stock had its “sector perform” rating restated by analysts at Royal Bank Of Canada in a research report issued on Wednesday,Digital Look reports. They presently have a GBX 1,350 price objective on the stock. Royal Bank Of Canada’s target price points to a potential upside of 18.53% from the company’s previous close.

Several other equities analysts have also issued reports on SN. Jefferies Financial Group restated a “buy” rating and set a GBX 2,760 price target on shares of Smith & Nephew in a research note on Thursday, May 21st. Berenberg Bank restated a “hold” rating and set a GBX 13 price target on shares of Smith & Nephew in a research note on Friday, May 1st. Finally, UBS Group restated a “neutral” rating and set a GBX 1,300 price target on shares of Smith & Nephew in a research note on Tuesday, May 5th. Three analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of GBX 1,382.63.

Get Smith & Nephew alerts:

Check Out Our Latest Report on Smith & Nephew

Smith & Nephew Stock Performance

LON SN opened at GBX 1,139 on Wednesday. The company has a quick ratio of 0.84, a current ratio of 2.57 and a debt-to-equity ratio of 62.90. The firm has a market cap of £12.49 billion, a PE ratio of 41.01, a PEG ratio of 0.46 and a beta of 0.67. The business’s fifty day simple moving average is GBX 1,163.63 and its 200-day simple moving average is GBX 1,221.87.

Smith & Nephew Company Profile

(Get Free Report)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

See Also

• Five stocks we like better than Smith & Nephew
• The Bank of Mom and Dad Is Booming—3 Stocks to Watch
• Corning Is Paving AI’s Future With Glass
• Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
• Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.